Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-Opioid receptorss

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 545-554

  Patkar, Kshitij A ^a   Wu, Jinhua ^a   Ganno, Michelle L ^a   Singh, Harminder D ^a   Ross, Nicolette C ^a   Rasakham, Khampaseuth ^b   Toll, Lawrence ^a   McLaughlin, Jay P ^a,b  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; NALOXONE; NORBINALTORPHIMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN HOMOGENATE; BRAIN MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ANALGESICS; ANIMALS; BENZENEACETAMIDES; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HOT TEMPERATURE; INJECTIONS, INTRAVENTRICULAR; MEMBRANES; MICE; MICE, INBRED C57BL; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84882348003     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.206086     Document Type: Article

References (43)

1. Akil H, Mayer DJ, and Liebeskind JC (1976) Antagonism of stimulation-produced analgesia by naloxone, a narcotic antagonist. Science 191:961-962.
2. Aldrich JV and McLaughlin JP (2009) Peptide k opioid receptor ligands: potential for drug development. AAPS J 11:312-322.
3. Aldrich JV and Vigil-Cruz S (2002) Narcotic analgesics, in Burger? s Medicinal Chemistry and Drug Discovery (Abraham D ed) John Wiley & Sons, Inc., New York.
4. Beardsley PM, Howard JL, Shelton KL, and Carroll FI (2005) Differential effects of the novel k opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 183:118-126.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. J Org Chem 47:248-254.
6. Broadbear JH, Negus SS, Butelman ER, de Costa BR, and Woods JH (1994)Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on k-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl) 115: 311-319.
7. Bruchas MR and Chavkin C (2010) Kinase cascades and ligand-directed signaling at the k opioid receptor. Psychopharmacology (Berl) 210:137-147.
8. Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, and Chavkin C (2007) Long-acting k opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282: 29803-29811.
9. Butelman ER, Negus SS, Ai Y, de Costa BR, and Woods JH (1993) k opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267:1269-1276.
10. Carey AN, Borozny K, Aldrich JV, and McLaughlin JP (2007) Reinstatement of cocaine place-conditioning prevented by the peptide k-opioid receptor antagonist arodyn. Eur J Pharmacol 569:84-89.
11. Carroll FI, Harris LS, and Aceto MD (2005) Effects of JDTic, a selective k-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. Eur J Pharmacol 524:89-94.
12. Chang AC, Takemori AE, Ojala WH, Gleason WB, and Portoghese PS (1994) k Opioid receptor selective affinity labels: electrophilic benzeneacetamides as k-selective opioid antagonists. J Med Chem 37:4490-4498.
13. Chen C, Yin J, Riel JK, DesJarlais RL, Raveglia LF, Zhu J, and Liu-Chen LY (1996) Determination of the amino acid residue involved in [3H]b-funaltrexamine covalent binding in the cloned rat m-opioid receptor. J Biol Chem 271:21422-21429.
14. Endoh T, Matsuura H, Tanaka C, and Nagase H (1992) Nor-binaltorphimine: a potent and selective k-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30-42.
15. Haley TJ and McCormick WG (1957) Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol Chemother 12:12-15.
16. Horan P, Taylor J, Yamamura HI, and Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260:1237-1243.
17. Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD, Woods JH, Lewis JW, and Traynor JR (2005) BU74, a complex oripavine derivative with potent k opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol 509:117-125.
18. Jones DN and Holtzman SG (1992) Long term k-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol 215:345-348.
19. Jones RM, Hjorth SA, Schwartz TW, and Portoghese PS (1998) Mutational evidence for a common k antagonist binding pocket in the wild-type k and mutant m[K303E] opioid receptors. J Med Chem 41:4911-4914.
20. Kam AY, Chan AS, and Wong YH (2004) k-opioid receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells. J Pharmacol Exp Ther 310:301-310.
21. Knoll AT, Meloni EG, Thomas JB, Carroll FI, and Carlezon WA, Jr. (2007) Anxiolyticlike effects of k-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323:838-845.
22. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC, Jr, Jones RM, Portoghese PS, and Carlezon WA, Jr. (2003) Antidepressant-like effects of k-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330.
23. Manfio JL, Santos VJ, Lanchote VL, Santos LM, Carmona MJ, Auler JO, Brum LJ, Donaduzzi CM, and Santos SR (2011) Development and validation of an HPLC/MS/ MS method for the determination of sufentanil and morphine in human plasma. J AOAC Int 94:136-142.
24. McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, and Bidlack JM (1999) Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of m-selective agonist and antagonist activity. J Pharmacol Exp Ther 289:304-311.
25. McLaughlin JP, Myers LC, Zarek PE, Caron MG, Lefkowitz RJ, Czyzyk TA, Pintar JE, and Chavkin C (2004) Prolonged k opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem 279:1810-1818.
26. Melief EJ, Miyatake M, Bruchas MR, and Chavkin C (2010) Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci USA 107:11608-11613.
27. Melief EJ, Miyatake M, Carroll FI, Béguin C, Carlezon WA, Jr, Cohen BM, Grimwood S, Mitch CH, Rorick-Kehn L, and Chavkin C (2011) Duration of action of a broad range of selective k-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activati on. Mol Pharmacol 80:920-929.
28. Metcalf MD and Coop A (2005) k opioid antagonists: past successes and future prospects. AAPS J 7:E704-E722.
29. Munro TA, Berry LM, Van?t Veer A, Béguin C, Carroll FI, Zhao Z, Carlezon WA, Jr, and Cohen BM (2012) Long-acting k opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol 12:1-18.
30. Neilan CL, Husbands SM, Breeden S, Ko MC, Aceto MD, Lewis JW, Woods JH, and Traynor JR (2004) Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting m-opioid receptor agonist. Eur J Pharmacol 499:107-116.
31. Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, Schroeder P, Sygowski LA, Piser TM, and Brugel TA (2011) Identification of short-acting k-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 661:27-34.
32. Portoghese PS, Lipkowski AW, and Takemori AE (1987) Binaltorphimine and norbinaltorphimine, potent and selective k-opioid receptor antagonists. Life Sci 40: 1287-1292.
33. Potter DN, Damez-Werno D, Carlezon WA, Jr, Cohen BM, and Chartoff EH (2011) Repeated exposure to the k-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 70: 744-753.
34. Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, and Liberto JG (2000) An open-label study of a functional opioid k antagonist in the treatment of opioid dependence. J Subst Abuse Treat 18:277-281.
35. Rothman RB, Long JB, Holaday JW, Bykov V, de Costa BR, Kim CH, Jacobson AE, and Rice KC (1989) A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivo. Neuropharmacology 28:1349-1356.
36. Stachulski AV and Meng X (2013) Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides. Nat Prod Rep 30:806-848.
37. Takemori AE, Ho BY, Naeseth JS, and Portoghese PS (1988) Nor-binaltorphimine, a highly selective k-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246:255-258.
38. Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, Xu H, Dersch CM, Lu Y, and Cantrell BE, et al. (2001) Identification of the first trans- (3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective k- opioid receptor antagonist activity. J Med Chem 44:2687-2690.
39. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O?Brien A, and White A, et al. (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-466.
40. Ward SJ, Portoghese PS, and Takemori AE (1982) Pharmacological profiles of b-funaltrexamine (b-FNA) and b-chlornaltrexamine (b-CNA) on the mouse vas deferens preparation. Eur J Pharmacol 80:377-384.
41. Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H, and Schwarzer C (2009) Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34:775-785.
42. Xu H, Kim CH, Zhu YC, Weber RJ, Jacobson AE, Rice KC, and Rothman RB (1991) (1)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the m opioid binding site: evidence for pseudoallosteric modulation. Neuropharmacology 30: 455-462.
43. Zhang H, Shi YG, Woods JH, Watson SJ, and Ko MC (2007) Central k-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol 570:89-96.